AHA Coding Clinic® for HCPCS - 2018 Quarter 2; For Your Information
New Multianalyte Assays with Algorithmic Analyses (MAAA) CPT codes
The AMA established three new CPT codes for the reporting of multianalyte assays with algorithmic analyses. The new CPT codes are listed in the table below. CPT Code Long Descriptor Effective Date 0011M Oncology, prostate cancer, mRNA expression assay of 12 genes (10 content and 2 housekeeping), RT-PCR test utilizing blood plasma and/or urine, algorithms to predict high-grade prostate cancer risk January 1, 2018 0012M Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and XCR2), utilizing urine, algorithm reported as a risk score for having urothelial carcinoma April 1...
Subscribe or sign in to view the full article.
Article Overview
This article is for coding professionals, laboratory billing teams, and oncology practices that track CPT updates for multianalyte assay services with algorithmic analyses. It explains a small set of new CPT additions, identifies the clinical areas they relate to, and notes when each became effective.
Why This Topic Matters
Updates to CPT reporting for laboratory assays can affect claim accuracy, charge capture, and coding workflows in oncology-related testing. Knowing which new codes were established and when they took effect helps staff stay aligned with current reporting requirements.
What You Will Learn
- Which new CPT reporting codes were established for multianalyte assay services
- The general oncology and urothelial testing areas covered by the new codes
- When each newly established code became effective
- How the article organizes the code information in table form
Who Should Read This
- Medical coders
- Coding auditors
- Laboratory billing staff
- Oncology practice administrators
- Revenue cycle professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com